Table 1. T3 N0 PMRT.
| Publication | No. of patients analysedT3N0 | Median age | Follow-up | PMRT | LRNI | Systemic therapy | Global failure T3 N0 | LRR in patients who received RT | Results | Multivariate and subgroup analysis |
|---|---|---|---|---|---|---|---|---|---|---|
| Maaret Helinto 1999 | 38 | 56 (35–84) | 58 months (4.83 years) | In 33 patients | Four patients | Tamoxifen (TMX) → 37% CMF → 18% |
5-year OS 72% DFS 77% LRR 18% |
LRR with RT 9% LRR 60% without RT P = 0.003 |
RT better DFS (p = 0.04) RT better OS (p = 0.03) |
No association found between factors |
| Scott R. Floyd 2006 | 70 | 50 | 85 months (7 years) | No | No | QT 41% TMX 24% Any systemic 56% |
LRR 7.6% DFS 87%, 82% y 78% at 5, 10 and 15 years OS 82%, 72, 68% at 5, 10 y 15 years |
LVI associated with lower OS (p = 0.0004), DFS (p = 0.023) and LRF (p = 0.017) |
– LVI(+) HR 6.6 for LRF (p = 0.038) HR 5.0 for OS (p = 0.002) HR 4.1 for DFS (p = 0.036) |
|
| Alphonse G. Tanghian 2006 | 313 | 49 (29–74) | No | No | QT 34% TMX 21.1% QT+TMX 19.2% |
Isolated LRF 8.9% Total LRF 10% Total DF 23% |
No independent factors were identified for LRR | |||
| Jennifer Goulart 2011 | 100 | PMRT7.5 years No PMRT 11.4 years |
PMRT 44% No PMRT 56% |
43% Chest wall y 57% Chest Wall and regional lymphnodes | PMRT – QT 50% – HT 64% No PMRT – QT 46% – HT 39% |
LRR 6% | LRR – PMRT 8.9% – No PMRT 2.3% (p = 0.2) BCSS – PMRT 85.8% – No PMRT 74.6% |
T3 > 5 cm better BCS HR 0.2; 95% CI 0.9*–0.6, p = 0.04) – Bigger tumours received more HT and PMRT Subgroup G3 presented 17% failure |
||
| Robert McCammon 2008 | SEER (1998–2002) N° 1844 patients |
No data | 10 years | PMRT 33.8% No PMRT 66.2% |
No data | No data | CSS inPMRT -- > HR 0.88 (p = 0.38) 10-year OS años – PMRT 70.7% – No PMRT 58.8% (p < 0.01) |
No data | OS – HR PMRT 0.69 p < 0.01 – HR in > 50 years = 0.41, p < 0.01 Grade 1 HR = 0.6, p < 0.01 |
|
| Matthew E. Johnson 2014 | SEER (2000–10) N° 2525 |
No data | 56 months (4.66 years) | PMRT 42.1% No PMRT 57.9% |
No data | No data | OS a 96 meses – PMRT 76.5% – No PMRT 61.8% (p < 0.01) CSS 96 meses – PMRT 85% – No PMRT82% (p < 0.01) |
PMRT had better OS – HR 0.63, p > 0.001 PMRT had better DSS – HR 0.77, p > 0.01 Histology grade I correlated with better OS and CSS |
||
| M Overgaard 82b 1997 | 135 patients T3N0 |
No data | 114 months (9.5 years) | PMRT – 58 patients No PMRT – 77 patients |
All with PMRT | 135 patients with CMF | 10-year DFS with PMRT 74% – No PMRT 62% 10-year OS – PMRT 82% versus No PMRT 70% |
LRR – with PMRT 3% – No PMRT 17% |
||
| M Overgaard1999 | 132 patients T3N0 | No data | 119 months(9.9 years) | PMRT – 68 patients No PMRT – 64 patients |
All with PMRT | All received TMX | 10-year DFS – PMRT 43% – No PMRT 40% 10-year OS – PMRT 56% – No PMRT 55% |
LRRwith PMRT 6% – without PMRT 23% |
||
| Yolanda D Tseng 2015 | 87 patientsT3N0 | No data | 50.1 months (4.17 años) | PMRT – 69 patients (79%) No PMRT – 18 patients (21%) |
No data | No LRR | ||||
| Mignano, John 2007 | 101 patients | 93 months (7.75 años) | No PMRT | No | LRR 11% without PMRT DF 11% without PMRT |
HT = Hormonal therapy; BCS= Breast cancer survival; LRNI= Locoregional lymph node irradiation